<DOC>
	<DOCNO>NCT00002216</DOCNO>
	<brief_summary>The purpose study compare 2 combination drug therapy HIV-infected patient never receive anti-HIV treatment .</brief_summary>
	<brief_title>A Comparison Two Multi-Drug Therapies HIV-Infected Patients Who Have Never Received Anti-HIV Treatment</brief_title>
	<detailed_description>In open-label study antiretroviral-naive patient randomize one two drug regimen : Arm I : 141W94 ( amprenavir ) , 1592U89 ( abacavir ) , Combivir ( 3TC/AZT tablet ) . Arm II : Nelfinavir Combivir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : CD4 count &gt; 50 . HIV RNA &gt; 5,000 . No active AIDS ( exclude CD4 count &lt; 200 ) . Ability comply dose schedule protocol evaluation . Prior Medication : Allowed : 3TC protease inhibitor , &lt; 1 week therapy . Other nucleoside analog , &lt; 4 week therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active AIDS ( include CD4 count &lt; 200 ) . Malabsorption syndrome affect drug absorption . Concurrent Medication : Excluded : Enrollment investigational drug protocol . Prior Medication : Excluded : Nonnucleoside reverse transcriptase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>